Go Pro
→ Porter flew 3,300 miles to investigate this system (From Porter & Company) (Ad)tc pixel Free BLSM Stock Alerts

BlossomHill Therapeutics (BLSM) Stock Forecast & Price Target

BlossomHill Therapeutics logo
$22.01 +1.99 (+9.94%)
As of 09/4/2026 04:00 PM Eastern

BlossomHill Therapeutics - Analysts' Recommendations and Stock Price Forecast (2026)

Consensus Rating

Moderate Buy
Based on 6 Analyst Ratings
Sell
0
Hold
1
Buy
5

Based on 6 Wall Street analysts who have issued ratings for BlossomHill Therapeutics in the last 12 months, the stock has a consensus rating of "Moderate Buy." Out of the 6 analysts, 1 has given a hold rating, and 5 have given a buy rating for BLSM.

Consensus Price Target

$32.20
46.30% Upside
According to the 6 analysts' twelve-month price targets for BlossomHill Therapeutics, the average price target is $32.20. The highest price target for BLSM is $36.00, while the lowest price target for BLSM is $28.00. The average price target represents a forecasted upside of 46.30% from the current price of $22.01.
MarketBeat calculates consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0 to .5 = Strong Sell, .5 to 1 = Sell, 1 to 1.5 = Reduce, 1.5 to 2.5 = Hold, 2.5 to 3.0 = Moderate Buy, 3.0 to 3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.
Get the Latest News and Ratings for BLSM and Related Stocks

Enter your email address to receive the latest news and analysts' ratings for BlossomHill Therapeutics and its competitors.

Sign Up
SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

BLSM Analyst Ratings Over Time

TypeCurrent Forecast
9/5/25 to 9/5/26		1 Month Ago
8/6/25 to 8/6/26		3 Months Ago
6/7/25 to 6/7/26		1 Year Ago
9/5/24 to 9/5/25
Strong Buy
0 Strong Buy rating(s)
 N/A N/A N/A
Buy
5 Buy rating(s)
 N/A N/A N/A
Hold
1 Hold rating(s)
 N/A N/A N/A
Sell
0 Sell rating(s)
 N/A N/A N/A
Consensus Price Target$32.20N/AN/AN/A
Forecasted Upside46.30% UpsideN/AN/AN/A
Consensus RatingModerate BuyN/AN/AN/A

BLSM Analyst Recommendations By Month

The chart below shows how a company's ratings by analysts have changed over time. Each bar represents the previous year of ratings for that month. Within each bar, the sell ratings are shown in red, the hold ratings are shown in yellow, the buy ratings are shown in green, and the strong buy ratings are shown in dark green.
Skip Chart & View Analyst Rating History

BLSM Price Targets by Month

The chart below shows how a company's share price and consensus price target have changed over time. The dark blue line represents the company's actual price. The lighter blue line represents the stock's consensus price target. The even lighter blue range in the background of the two lines represents the low price target and the high price target for each stock.
Skip Chart and View Analyst Price Target HistorySkip Chart & View Price History Table

BlossomHill Therapeutics Stock vs. The Competition

TypeBlossomHill Therapeutics CompaniesBroader Market
Consensus Rating Score
2.83
1.68
2.53
Consensus RatingModerate BuyReduceModerate Buy
Predicted Upside46.30% Upside153.02% Upside14.02% Upside
News Sentiment Rating
Positive News

See Recent BLSM News
Positive News
Positive News
Export
DateBrokerageAnalystActionRatingPrice TargetReport Date
Upside/Downside		Details
9/2/2026
Zacks Research logo
Zacks Research
5 of 5 stars
 UpgradeHold
9/1/2026
Leerink Partners logo
Leerink Partners
2 of 5 stars
 Initiated CoverageOutperform$36.00+93.34%
9/1/2026
Guggenheim logo
Guggenheim
5 of 5 stars
Michael Schmidt
Michael Schmidt
5 of 5 stars
Initiated CoverageBuy$30.00+63.93%
9/1/2026
HC Wainwright logo
HC Wainwright
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Robert Burns
Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating
Initiated CoverageBuy$35.00+91.26%
9/1/2026
Lifesci Capital logo
Lifesci Capital
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
 Initiated CoverageOutperform$32.00+72.41%
9/1/2026
JPMorgan Chase & Co. logo
JPMorgan Chase & Co.
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Brian Cheng
Brian Cheng
Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating
Initiated CoverageOverweight$28.00+53.01%

Analyst ratings data on MarketBeat is provided by Benzinga and other data providers. This page was last refreshed on Saturday at 07:47 AM ET.


BLSM Forecast - Frequently Asked Questions

According to the research reports of 6 Wall Street equities research analysts, the average twelve-month stock price forecast for BlossomHill Therapeutics is $32.20, with a high forecast of $36.00 and a low forecast of $28.00.

6 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for BlossomHill Therapeutics in the last year. There is currently 1 hold rating and 5 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "moderate buy" BLSM shares.

According to analysts, BlossomHill Therapeutics's stock has a predicted upside of 46.30% based on their 12-month stock forecasts.

Over the previous 90 days, BlossomHill Therapeutics's stock had 1 upgrade by analysts.

BlossomHill Therapeutics has been rated by research analysts at Guggenheim, HC Wainwright, JPMorgan Chase & Co., Leerink Partners, Lifesci Capital, and Zacks Research in the past 90 days.

Analysts like BlossomHill Therapeutics more than other "" companies. The consensus rating for BlossomHill Therapeutics is Moderate Buy while the average consensus rating for "" companies is Reduce. Learn more on how BLSM compares to other companies.

Today's Analyst Ratings

Top-Rated Stocks

More Ratings Tools

Brokerages With BlossomHill Therapeutics Recommendations


MarketBeat monitors more than a dozen sources for BlossomHill Therapeutics analyst ratings, with the most recent rating issued on 9/2/2026.
From Our Partners
ALERT: Drop these 5 stocks before the market opens tomorrow!
The Wall Street Journal is already raising the alarm about a potential market crash, and Weiss Ratings researc...
Weiss Ratings | Sponsoredtc pixel
Small Colorado Company (Backed by Sam Altman) Could Save U.S. Power Grid
A small Colorado company has secured rights to technology that could prevent the U.S. public power grid from c...
Altimetry | Sponsoredtc pixel
Louis Navellier: My #1 AI stock for 2026 (name & ticker inside)
Louis Navellier's Stock Grader system helped him flag Nvidia before its 82,000% run and has identified the top...
InvestorPlace | Sponsoredtc pixel
Ready to give options a try? Your first trade (Ticker included) -INSIDE
Tired of trying tactic after tactic when it comes to options trades... only to be met with market noise and st...
Base Camp Trading | Sponsoredtc pixel
The $15 Gold Fund That Pays Up to $1,152/Month
Gold is hitting record highs, but most investors are leaving income on the table. A $15 fund is quietly paying...
Investors Alley | Sponsoredtc pixel
Iran War Shock: What I Was Told In That Private Meeting
You’re Being LIED To About The Iran War Forget EVERYTHING you’ve heard about the Iran war. Especially th...
Banyan Hill Publishing | Sponsoredtc pixel
My top 3 AI picks for the next decade
Alexander Green bought Apple in 1996, recommended Nvidia at a split-adjusted 66 cents in 2004, and picked up A...
The Oxford Club | Sponsoredtc pixel
Here’s the stock symbol I’ve promised
Whitney Tilson of Stansberry Research has long recommended Berkshire Hathaway as a core retirement holding - b...
Stansberry Research | Sponsoredtc pixel